Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 18/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899784 | 0.73 | CYP11B2 (0.31) | CYP11B2 | |
| SCHEMBL1040633 | 0.72 | CYP19A1 (0.52) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 | |
| SCHEMBL31326542 | 0.71 | CYP11B2 (0.85) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 | |
| SCHEMBL1036346 | 0.71 | CYP11B2 (0.66) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 | |
| SCHEMBL1040554 | 0.71 | CYP11B2 (0.85) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 | |
| SCHEMBL13563929 | 0.70 | CYP11B2 (0.83) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 | |
| SCHEMBL1040490 | 0.69 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL8238659 | 0.69 | CYP11B2 (0.79) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 | |
| SCHEMBL1040054 | 0.69 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL1037792 | 0.69 | CYP11B2 (0.64) | CYP11B2CYP19A1CYP11B1CYP17A1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016109361-A2 | 3-FLUORO-BENZONITRILE INHIBITORS OF 11-BETA-HYDROXYLASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |